Unknown

Dataset Information

0

Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.

ABSTRACT: The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup has organized an annual workshop focused on minimal residual disease (MRD) testing and immune profiling (IP) in multiple myeloma since 2016. In 2019, the workshop took place as an American Society of Hematology (ASH) Friday Scientific Workshop titled "Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma." This workshop focused on 4 main topics: the molecular and immunologic evolution of plasma cell disorders, development of new laboratory- and imaging-based MRD assessment approaches, chimeric antigen receptor T cell therapy research, and statistical and regulatory issues associated with novel clinical endpoints. In this report, we provide a summary of the workshop and discuss future directions.

SUBMITTER: Holstein SA 

PROVIDER: S-EPMC7529908 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.

Holstein Sarah A SA   Howard Alan A   Avigan David D   Bhutani Manisha M   Cohen Adam D AD   Costa Luciano J LJ   Dhodapkar Madhav V MV   Gay Francesca F   Gormley Nicole N   Green Damian J DJ   Hillengass Jens J   Korde Neha N   Li Zihai Z   Mailankody Sham S   Neri Paola P   Parekh Samir S   Pasquini Marcelo C MC   Puig Noemi N   Roodman G David GD   Samur Mehmet Kemal MK   Shah Nina N   Shah Urvi A UA   Shi Qian Q   Spencer Andrew A   Suman Vera J VJ   Usmani Saad Z SZ   McCarthy Philip L PL  

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20200624 10

The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup has organized an annual workshop focused on minimal residual disease (MRD) testing and immune profiling (IP) in multiple myeloma since 2016. In 2019, the workshop took place as an American Society of Hematology (ASH) Friday Scientific Workshop titled "Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma." This workshop focused on 4 main topics: the molecular and immunologic evolution of plas  ...[more]

Similar Datasets

Unknown Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
| S-EPMC6942175 | biostudies-literature
Unknown Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
| S-EPMC6445685 | biostudies-literature
Unknown BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee.
| S-EPMC5902638 | biostudies-literature
Unknown Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma.
| S-EPMC9357156 | biostudies-literature
Unknown The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.
| S-EPMC8478786 | biostudies-literature
Unknown Level of Clonal Plasma Cells in Hematopoietic Cell Autografts Reflects the Pre-Transplant Bone Marrow Minimal Residual Disease in Multiple Myeloma Patients.
| S-EPMC11886492 | biostudies-literature
Unknown Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma.
| S-EPMC8945288 | biostudies-literature
Unknown Flow Cytometric Analysis of Bone Marrow Particle Cells for Measuring Minimal Residual Disease in Multiple Myeloma.
| S-EPMC9563644 | biostudies-literature
Unknown B-Cell Regeneration Profile and Minimal Residual Disease Status in Bone Marrow of Treated Multiple Myeloma Patients.
| S-EPMC8038337 | biostudies-literature
Unknown Clonotypic Light Chain Peptides Identified for Monitoring Minimal Residual Disease in Multiple Myeloma without Bone Marrow Aspiration.
| S-EPMC5003037 | biostudies-literature